Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Esophageal Neoplasms 7Breast Neoplasms 6Stomach Neoplasms 4Uterine Cervical Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Thymoma 1Small Cell Lung Carcinoma 1Recurrence 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Fibrosis Of Extraocular Muscles, Congenital, 3A, with or without Extraocular Involvement 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1EGFR Positive Non-small Cell Lung Cancer 1Carcinoma, Ovarian Epithelial 1Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction 1

Interventions

Paclitaxel 1Gemcitabine 1Doxorubicin 1Cyclophosphamide 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Fibrosis Of Extraocular Muscles, Congenital, 3A, with or without Extraocular Involvement × Paclitaxel × Clear all
NCT06531447 2024-08-01

First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients

The National Center of Oncology, Azerbaijan

Phase 2 Active not recruiting
200 enrolled
Breast

Fibrosis Of Extraocular Muscles, Congenital, 3A, with or without Extraocular Involvement, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡